Skip to main content
NCBI home page
CMAJ : Canadian Medical Association Journal logoLink to CMAJ : Canadian Medical Association Journal
. 1997 Oct 15;157(8):1061–1067.

Pharmacologic treatment of depression in late life

A J Flint 1
PMCID: PMC1228262  PMID: 9347777

Abstract

A number of age-related factors, including changes in pharmacokinetics and pharmacodynamics, medical comorbidity and an increased risk of drug-drug interaction, can complicate the pharmacologic management of depression in late life. Nevertheless, over 80% of elderly depressed patients will eventually respond to vigorous treatment and, when treated over 2 years, up to 75% of those will not have a relapse or recurrence of depression. This article reviews a number of issues relating to the pharmacotherapy of depression in elderly people. In particular, it discusses the similarities and differences between various antidepressant medications, issues pertaining to dosing and length of treatment, and management of the patient who does not respond to first-line treatment. The author emphasizes that, because of the high risk of relapse and recurrence, a long-term collaboration between the patient and the physician is required to successfully manage depression in late life.

Full Text

The Full Text of this article is available as a PDF (120.3 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Baldwin D. S., Hawley C. J., Abed R. T., Maragakis B. P., Cox J., Buckingham S. A., Pover G. H., Ascher A. A multicenter double-blind comparison of nefazodone and paroxetine in the treatment of outpatients with moderate-to-severe depression. J Clin Psychiatry. 1996;57 (Suppl 2):46–52. [PubMed] [Google Scholar]
  2. Barbhaiya R. H., Buch A. B., Greene D. S. A study of the effect of age and gender on the pharmacokinetics of nefazodone after single and multiple doses. J Clin Psychopharmacol. 1996 Feb;16(1):19–25. doi: 10.1097/00004714-199602000-00004. [DOI] [PubMed] [Google Scholar]
  3. Brown W. A., Harrison W. Are patients who are intolerant to one serotonin selective reuptake inhibitor intolerant to another? J Clin Psychiatry. 1995 Jan;56(1):30–34. [PubMed] [Google Scholar]
  4. DeVane C. L. Pharmacokinetics of the selective serotonin reuptake inhibitors. J Clin Psychiatry. 1992 Feb;53 (Suppl):13–20. [PubMed] [Google Scholar]
  5. Feighner J. P. The role of venlafaxine in rational antidepressant therapy. J Clin Psychiatry. 1994 Sep;55 (Suppl A):62-8; discussion 69-70, 98-100. [PubMed] [Google Scholar]
  6. Flint A. J., Crosby J., Genik J. L. Recurrent hyponatremia associated with fluoxetine and paroxetine. Am J Psychiatry. 1996 Jan;153(1):134–134. doi: 10.1176/ajp.153.1.134a. [DOI] [PubMed] [Google Scholar]
  7. Flint A. J., Rifat S. L. The effect of sequential antidepressant treatment on geriatric depression. J Affect Disord. 1996 Jan 22;36(3-4):95–105. doi: 10.1016/0165-0327(95)00063-1. [DOI] [PubMed] [Google Scholar]
  8. Flint A. J., Rifat S. L. The effect of treatment on the two-year course of late-life depression. Br J Psychiatry. 1997 Mar;170:268–272. doi: 10.1192/bjp.170.3.268. [DOI] [PubMed] [Google Scholar]
  9. Georgotas A., Forsell T. L., Mann J. J., Kim M., Gershon S. Trazodone hydrochloride: a wide spectrum antidepressant with a unique pharmacological profile. A review of its neurochemical effects, pharmacology, clinical efficacy, and toxicology. Pharmacotherapy. 1982 Sep-Oct;2(5):255–265. doi: 10.1002/j.1875-9114.1982.tb03193.x. [DOI] [PubMed] [Google Scholar]
  10. Georgotas A., McCue R. E., Cooper T. B., Nagachandran N., Chang I. How effective and safe is continuation therapy in elderly depressed patients? Factors affecting relapse rate. Arch Gen Psychiatry. 1988 Oct;45(10):929–932. doi: 10.1001/archpsyc.1988.01800340057008. [DOI] [PubMed] [Google Scholar]
  11. Geretsegger C., Böhmer F., Ludwig M. Paroxetine in the elderly depressed patient: randomized comparison with fluoxetine of efficacy, cognitive and behavioural effects. Int Clin Psychopharmacol. 1994 Spring;9(1):25–29. [PubMed] [Google Scholar]
  12. Goodnick P. J. Pharmacokinetic optimisation of therapy with newer antidepressants. Clin Pharmacokinet. 1994 Oct;27(4):307–330. doi: 10.2165/00003088-199427040-00005. [DOI] [PubMed] [Google Scholar]
  13. Grimsley S. R., Jann M. W. Paroxetine, sertraline, and fluvoxamine: new selective serotonin reuptake inhibitors. Clin Pharm. 1992 Nov;11(11):930–957. [PubMed] [Google Scholar]
  14. Halper J. P., Mann J. J. Cardiovascular effects of antidepressant medications. Br J Psychiatry Suppl. 1988 Sep;(3):87–98. [PubMed] [Google Scholar]
  15. Harris M. G., Benfield P. Fluoxetine. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in older patients with depressive illness. Drugs Aging. 1995 Jan;6(1):64–84. doi: 10.2165/00002512-199506010-00006. [DOI] [PubMed] [Google Scholar]
  16. Harvey A. T., Preskorn S. H. Cytochrome P450 enzymes: interpretation of their interactions with selective serotonin reuptake inhibitors. Part II. J Clin Psychopharmacol. 1996 Oct;16(5):345–355. doi: 10.1097/00004714-199610000-00002. [DOI] [PubMed] [Google Scholar]
  17. Hirschfeld R. M. Long-term drug treatment of unipolar depression. Int Clin Psychopharmacol. 1996 Dec;11(4):211–217. doi: 10.1097/00004850-199612000-00001. [DOI] [PubMed] [Google Scholar]
  18. Joffe R. T., Levitt A. J., Sokolov S. T., Young L. T. Response to an open trial of a second SSRI in major depression. J Clin Psychiatry. 1996 Mar;57(3):114–115. [PubMed] [Google Scholar]
  19. Katz I. R., Simpson G. M., Curlik S. M., Parmelee P. A., Muhly C. Pharmacologic treatment of major depression for elderly patients in residential care settings. J Clin Psychiatry. 1990 Jul;51 (Suppl):41–48. [PubMed] [Google Scholar]
  20. Koenig H. G., Breitner J. C. Use of antidepressants in medically ill older patients. Psychosomatics. 1990 Winter;31(1):22–32. doi: 10.1016/S0033-3182(90)72213-X. [DOI] [PubMed] [Google Scholar]
  21. Lipsey J. R., Robinson R. G., Pearlson G. D., Rao K., Price T. R. Nortriptyline treatment of post-stroke depression: a double-blind study. Lancet. 1984 Feb 11;1(8372):297–300. doi: 10.1016/s0140-6736(84)90356-8. [DOI] [PubMed] [Google Scholar]
  22. Liu B. A., Mittmann N., Knowles S. R., Shear N. H. Hyponatremia and the syndrome of inappropriate secretion of antidiuretic hormone associated with the use of selective serotonin reuptake inhibitors: a review of spontaneous reports. CMAJ. 1996 Sep 1;155(5):519–527. [PMC free article] [PubMed] [Google Scholar]
  23. Miller M. D., Pollock B. G., Rifai A. H., Paradis C. F., Perel J. M., George C., Stack J. A., Reynolds C. F., 3rd Longitudinal analysis of nortriptyline side effects in elderly depressed patients. J Geriatr Psychiatry Neurol. 1991 Oct-Dec;4(4):226–230. doi: 10.1177/089198879100400409. [DOI] [PubMed] [Google Scholar]
  24. Mulsant B. H., Rosen J., Thornton J. E., Zubenko G. S. A prospective naturalistic study of electroconvulsive therapy in late-life depression. J Geriatr Psychiatry Neurol. 1991 Jan-Mar;4(1):3–13. doi: 10.1177/089198879100400102. [DOI] [PubMed] [Google Scholar]
  25. Nemeroff C. B., DeVane C. L., Pollock B. G. Newer antidepressants and the cytochrome P450 system. Am J Psychiatry. 1996 Mar;153(3):311–320. doi: 10.1176/ajp.153.3.311. [DOI] [PubMed] [Google Scholar]
  26. Newhouse P. A. Use of serotonin selective reuptake inhibitors in geriatric depression. J Clin Psychiatry. 1996;57 (Suppl 5):12–22. [PubMed] [Google Scholar]
  27. Preskorn S. H. Recent pharmacologic advances in antidepressant therapy for the elderly. Am J Med. 1993 May 24;94(5A):2S–12S. [PubMed] [Google Scholar]
  28. Prien R. F., Kupfer D. J. Continuation drug therapy for major depressive episodes: how long should it be maintained? Am J Psychiatry. 1986 Jan;143(1):18–23. doi: 10.1176/ajp.143.1.18. [DOI] [PubMed] [Google Scholar]
  29. Reynolds C. F., 3rd, Frank E., Kupfer D. J., Thase M. E., Perel J. M., Mazumdar S., Houck P. R. Treatment outcome in recurrent major depression: a post hoc comparison of elderly ("young old") and midlife patients. Am J Psychiatry. 1996 Oct;153(10):1288–1292. doi: 10.1176/ajp.153.10.1288. [DOI] [PubMed] [Google Scholar]
  30. Rickels K., Schweizer E. Clinical overview of serotonin reuptake inhibitors. J Clin Psychiatry. 1990 Dec;51 (Suppl B):9–12. [PubMed] [Google Scholar]
  31. Robinson D. S., Roberts D. L., Smith J. M., Stringfellow J. C., Kaplita S. B., Seminara J. A., Marcus R. N. The safety profile of nefazodone. J Clin Psychiatry. 1996;57 (Suppl 2):31–38. [PubMed] [Google Scholar]
  32. Rockwell E., Lam R. W., Zisook S. Antidepressant drug studies in the elderly. Psychiatr Clin North Am. 1988 Mar;11(1):215–233. [PubMed] [Google Scholar]
  33. Roose S. P., Dalack G. W. Treating the depressed patient with cardiovascular problems. J Clin Psychiatry. 1992 Sep;53 (Suppl):25–31. [PubMed] [Google Scholar]
  34. Roose S. P., Glassman A. H. Antidepressant choice in the patient with cardiac disease: lessons from the Cardiac Arrhythmia Suppression Trial (CAST) studies. J Clin Psychiatry. 1994 Sep;55 (Suppl A):83-7; discussion 88-9, 98-100. [PubMed] [Google Scholar]
  35. Sadavoy J., Reiman-Sheldon E. General hospital geriatric psychiatric treatment: a follow-up study. J Am Geriatr Soc. 1983 Apr;31(4):200–205. doi: 10.1111/j.1532-5415.1983.tb05095.x. [DOI] [PubMed] [Google Scholar]
  36. Shader R. I., von Moltke L. L., Schmider J., Harmatz J. S., Greenblatt D. J. The clinician and drug interactions--an update. J Clin Psychopharmacol. 1996 Jun;16(3):197–201. doi: 10.1097/00004714-199606000-00001. [DOI] [PubMed] [Google Scholar]
  37. Sheline Y. I., Freedland K. E., Carney R. M. How safe are serotonin reuptake inhibitors for depression in patients with coronary heart disease? Am J Med. 1997 Jan;102(1):54–59. doi: 10.1016/s0002-9343(96)00374-9. [DOI] [PubMed] [Google Scholar]
  38. Thase M. E., Blomgren S. L., Birkett M. A., Apter J. T., Tepner R. G. Fluoxetine treatment of patients with major depressive disorder who failed initial treatment with sertraline. J Clin Psychiatry. 1997 Jan;58(1):16–21. doi: 10.4088/jcp.v58n0103. [DOI] [PubMed] [Google Scholar]
  39. Thomas D. R., Nelson D. R., Johnson A. M. Biochemical effects of the antidepressant paroxetine, a specific 5-hydroxytryptamine uptake inhibitor. Psychopharmacology (Berl) 1987;93(2):193–200. doi: 10.1007/BF00179933. [DOI] [PubMed] [Google Scholar]
  40. Warrington S. J. Clinical implications of the pharmacology of sertraline. Int Clin Psychopharmacol. 1991 Dec;6 (Suppl 2):11–21. doi: 10.1097/00004850-199112002-00004. [DOI] [PubMed] [Google Scholar]
  41. Zisselman M. H., Rovner B. W., Shmuely Y. Benzodiazepine use in the elderly prior to psychiatric hospitalization. Psychosomatics. 1996 Jan-Feb;37(1):38–42. doi: 10.1016/S0033-3182(96)71596-7. [DOI] [PubMed] [Google Scholar]
  42. de Vries M. H., Raghoebar M., Mathlener I. S., van Harten J. Single and multiple oral dose fluvoxamine kinetics in young and elderly subjects. Ther Drug Monit. 1992 Dec;14(6):493–498. doi: 10.1097/00007691-199212000-00010. [DOI] [PubMed] [Google Scholar]
  43. van Laar M. W., van Willigenburg A. P., Volkerts E. R. Acute and subchronic effects of nefazodone and imipramine on highway driving, cognitive functions, and daytime sleepiness in healthy adult and elderly subjects. J Clin Psychopharmacol. 1995 Feb;15(1):30–40. doi: 10.1097/00004714-199502000-00006. [DOI] [PubMed] [Google Scholar]

Articles from CMAJ: Canadian Medical Association Journal are provided here courtesy of Canadian Medical Association

RESOURCES